CagriSema vs Zepbound: The Pipeline Challenger, Measured

CagriSema (cagrilintide + semaglutide, Novo Nordisk) vs Zepbound (tirzepatide, Eli Lilly)

Last verified November 2026

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The verdict

About 20.4% at 68 weeks for CagriSema in REDEFINE-1 (PMID 40544433) against up to about 20.9% at 72 weeks for Zepbound's 15 mg arm in SURMOUNT-1 (PMID 35658024). Those placebo-trial figures look level, but the drugs have since met head to head. In the open-label REDEFINE 4 trial in 809 adults with obesity, weight fell 20.2% on CagriSema 2.4 mg against 23.6% on tirzepatide 15 mg at 84 weeks, and CagriSema missed its primary endpoint of non-inferiority. In type 2 diabetes, REIMAGINE 4 found 15.2% against 15.8% at the top doses, assuming everyone stayed on treatment; at lower doses, REIMAGINE 5 reported 12.4% for CagriSema 1.0 mg against 9.1% for tirzepatide 5 mg. All three results come from Novo Nordisk and none is yet published in a journal. CagriSema is under FDA review and not for sale; Zepbound is prescribable at $299–$449 a month through LillyDirect.

Side-by-side comparison

CagriSema vs Zepbound, side by side
FieldCagriSemaZepbound
Peak weight loss (vs placebo)~20.4% at 68 wk — REDEFINE-1 (PMID 40544433)Up to ~20.9% (15 mg arm) at 72 wk — SURMOUNT-1 (PMID 35658024)
Head-to-head dataREDEFINE 4 (obesity, 84 wk): −20.2%, missed non-inferiority; REIMAGINE 4 (T2D, 68 wk): −15.2%; REIMAGINE 5 (T2D, 1.0 mg, 60 wk): −12.4%. REDEFINE 4 counts everyone randomized; REIMAGINE 4 assumes everyone stayed on treatment. Company-reported, unpublishedREDEFINE 4: −23.6% (15 mg); REIMAGINE 4: −15.8% (15 mg); REIMAGINE 5: −9.1% (5 mg)
Mechanism of actionAmylin receptor + GLP-1 receptor agonist (cagrilintide + semaglutide 2.4 mg)Dual GIP receptor + GLP-1 receptor agonist (tirzepatide)
FDA approval statusInvestigational — NDA filed December 2025; no FDA decision as of November 2026FDA-approved for chronic weight management since November 2023
Cardiovascular outcomesNo completed CV outcomes trial; data pendingSURMOUNT-MMO trial ongoing; CV indication not yet approved
AdministrationOnce-weekly subcutaneous injection (investigational dosing)Once-weekly subcutaneous injection (2.5–15 mg, dose escalation)
Commercial availability & priceNot commercially available — clinical trials onlyAvailable by prescription; $299–$449/mo via LillyDirect Self Pay (KwikPen)

What each one costs in the compounded market

Standing monthly cash prices from the 734 sellers on this register. These are compounded preparations, not the approved products compared above.

CagriSema — cagrilintide + semaglutide

No seller on this register publishes a compounded price for it. For a drug still in trials that is expected — and anyone selling it anyway is doing so outside the system this register covers.

Zepbound — tirzepatide

from $69 /mo

453 sellers publish a standing price. This is the lowest of all 453; the median is $228.28 a month.

Where to get tirzepatide — a selection of sellers, not a price ranking

⚠ A compounded preparation is not the approved product. No agency has reviewed that specific preparation for safety, effectiveness or manufacturing quality, and the legal ground under compounding these molecules narrowed when the shortages closed. The price gap is real, and so is the difference in oversight. Every seller, with its price record.

Frequently asked questions

Which works better for weight loss, CagriSema or Zepbound?

On the trial evidence, neither clearly. CagriSema recorded ~20.4% at 68 wk — REDEFINE-1 (PMID 40544433) and Zepbound Up to ~20.9% (15 mg arm) at 72 wk — SURMOUNT-1 (PMID 35658024), and the head-to-head comparison put CagriSema at REDEFINE 4 (obesity, 84 wk): −20.2%, missed non-inferiority; REIMAGINE 4 (T2D, 68 wk): −15.2%; REIMAGINE 5 (T2D, 1.0 mg, 60 wk): −12.4%. REDEFINE 4 counts everyone randomized; REIMAGINE 4 assumes everyone stayed on treatment. Company-reported, unpublished against Zepbound at REDEFINE 4: −23.6% (15 mg); REIMAGINE 4: −15.8% (15 mg); REIMAGINE 5: −9.1% (5 mg). A head-to-head is the strongest form of this evidence because both arms run under one protocol — separate trials are not directly comparable however alike they look.

Are CagriSema and Zepbound the same drug?

No. CagriSema is cagrilintide + semaglutide and Zepbound is tirzepatide — different molecules, and they work differently: Amylin receptor + GLP-1 receptor agonist (cagrilintide + semaglutide 2.4 mg) against Dual GIP receptor + GLP-1 receptor agonist (tirzepatide). Results with one do not predict results with the other.

Is CagriSema or Zepbound cheaper?

On the manufacturers' own cash pricing: CagriSema at Not commercially available — clinical trials only, Zepbound at Available by prescription; $299–$449/mo via LillyDirect Self Pay (KwikPen). That is the list-price comparison, and it is not what most people pay. What you actually pay depends on whether your plan covers it, which formulary tier it sits in, and whether you have met your deductible — and for many people the honest comparison is between an insured copay and a cash-pay compounded alternative rather than between these two figures.

Does either one have better cardiovascular evidence?

Neither has a clear edge does. CagriSema: No completed CV outcomes trial; data pending. Zepbound: SURMOUNT-MMO trial ongoing; CV indication not yet approved. This matters more than it first appears — a drug with a completed outcomes trial has evidence about events that matter, not only about weight, and that is often what decides coverage.

How is each one taken?

CagriSema: Once-weekly subcutaneous injection (investigational dosing). Zepbound: Once-weekly subcutaneous injection (2.5–15 mg, dose escalation). Worth weighing honestly against your own habits — the best drug for you is partly the one you will still be taking in eight months, and a dosing routine that does not fit a life gets abandoned.

What does a compounded version of each actually cost?

Across the 734 sellers in this register, the cheapest standing monthly cash prices we hold are tirzepatide from $69 a month. A compounded preparation is not the approved product: no agency has reviewed that specific preparation for safety, effectiveness or manufacturing quality, and the legal ground under compounding these molecules narrowed once the shortages closed. The price gap is real and so is the difference in oversight.

Can I switch from CagriSema to Zepbound?

Yes, with a prescriber. Expect to re-titrate from the bottom of the new drug's ladder rather than starting where you left off: these are different molecules and tolerance to one does not transfer to the other. Both the old drug's washout and the new drug's schedule apply.

Which one should I ask for?

That is a prescriber's call, and anyone answering it from a table is guessing. What a page like this can do is tell you what the trials measured, what the manufacturers charge, and where the evidence is still missing, so the conversation starts from the record rather than from an advertisement.

References

  1. 1.Garvey WT, Blüher M, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1) N Engl J Med. 2025;393(7):635-647. 2025. PMID: 40544433.
  2. 2.Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) N Engl J Med. 2022;387(3):205-216. 2022. PMID: 35658024.
  3. 3.Davies MJ, Bajaj HS, et al. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes (REDEFINE 2) N Engl J Med. 2025;393(7):648-659. 2025. PMID: 40544432.
  4. 4.Yamauchi T, Becker NP, Hagemann CA, et al. Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity Lancet Diabetes Endocrinol. 2026;14(6):450-462. 2026. PMID: 42009015.
  5. 5.Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) N Engl J Med. 2021;384(11):989-1002. 2021. PMID: 33567185.
  6. 6.Novo Nordisk A/S CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved (Form 6-K) U.S. Securities and Exchange Commission, February 23, 2026. 2026. https://www.sec.gov/Archives/edgar/data/353278/000117184326000996/f6k_022326.htm
  7. 7.Novo Nordisk A/S Financial report for the first six months of 2026 (Form 6-K), REIMAGINE 4 entry U.S. Securities and Exchange Commission, August 4, 2026. 2026. https://www.sec.gov/Archives/edgar/data/353278/000035327826000023/caq22026.htm
  8. 8.Novo Nordisk A/S Novo's CagriSema delivers superior weight loss versus tirzepatide in REIMAGINE 5 trial Novo Nordisk news release, September 21, 2026. 2026. https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916774
  9. 9.Novo Nordisk A/S Financial report for the period 1 January 2026 to 30 September 2026 (Form 6-K) U.S. Securities and Exchange Commission, November 4, 2026. 2026. https://www.sec.gov/Archives/edgar/data/353278/000162828026069805/caq32026.htm

See the full drug-vs-drug verdict index or provider rankings.